IMAC (NASDAQ:IMAC) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

IMAC (NASDAQ:IMACGet Rating) posted its quarterly earnings data on Friday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03), MarketWatch Earnings reports. IMAC had a negative net margin of 73.27% and a negative return on equity of 41.54%.

Shares of IMAC traded up $0.03 during mid-day trading on Friday, hitting $0.83. The company’s stock had a trading volume of 367,404 shares, compared to its average volume of 155,668. IMAC has a one year low of $0.75 and a one year high of $2.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a market capitalization of $21.99 million, a PE ratio of -3.19 and a beta of -1.36. The stock’s 50-day moving average is $0.91 and its two-hundred day moving average is $1.12.

An institutional investor recently bought a new position in IMAC stock. Citadel Advisors LLC acquired a new stake in IMAC Holdings, Inc. (NASDAQ:IMACGet Rating) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 75,398 shares of the company’s stock, valued at approximately $149,000. Citadel Advisors LLC owned 0.30% of IMAC at the end of the most recent quarter. Institutional investors and hedge funds own 24.27% of the company’s stock.

About IMAC (Get Rating)

IMAC Holdings, Inc owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains.

Further Reading

Earnings History for IMAC (NASDAQ:IMAC)

Receive News & Ratings for IMAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMAC and related companies with's FREE daily email newsletter.